Lb Pharmaceuticals (LBRX) Enterprise Value (2025 - 2026)

Lb Pharmaceuticals' Enterprise Value history runs 3 years deep, the most recent figure standing at -$365.6 million for Q1 2026.

• In Q1 2026, Enterprise Value changed N/A year-over-year to -$365.6 million; the TTM figure through Mar 2026 stood at -$365.6 million (changed N/A YoY), while the FY2025 annual figure was -$295.2 million, down 954.37% from the prior year.
• Enterprise Value for Q1 2026 stood at -$365.6 million, down from -$295.2 million in the prior quarter.
• The five-year high for Enterprise Value was -$28.0 million in Q4 2024, with the low at -$365.6 million in Q1 2026.
• The 3-year median for Enterprise Value is -$304.8 million (2025), against an average of -$250.8 million.
• Peak annual rise in Enterprise Value reached 954.37% in 2025, while the deepest fall reached 954.37% in 2025.
• Lb Pharmaceuticals' Enterprise Value stood at -$28.0 million in 2024, then plunged by 954.37% to -$295.2 million in 2025, then dropped by 23.85% to -$365.6 million in 2026.
• Business Quant data shows LBRX's Enterprise Value at -$365.6 million in Q1 2026, -$295.2 million in Q4 2025, and -$314.5 million in Q3 2025.